Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease

Neurochemistry International

Volumn 54, Issue 7, 2009, Pages 418-425

  Pan, Jing ^a,b   Xiao, Qin ^a   Sheng, Cheng Yu ^b   Hong, Zhen ^a   Yang, Hong Qi ^a   Wang, Gang ^a   Ding, Jian Qing ^a,b   Chen, Sheng Di ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Activation; JNK3; Ketamine; N Acetylcysteine; Parkinson's disease; Translocation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; ACETYLCYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE 10; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACETYLCYSTEINE; ANIMALS; BLOTTING, WESTERN; CELL NUCLEUS; DOPAMINE; DOPAMINE AGENTS; ENZYME ACTIVATION; EXCITATORY AMINO ACID ANTAGONISTS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KETAMINE; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 10; NEOSTRIATUM; NEURONS; PARKINSON DISEASE; PROTEIN TRANSPORT; QUINOXALINES; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 63149175770     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.01.013     Document Type: Article

References (40)

1. Anantharam V., Lehrmann E., Kanthasamy A., Yang Y., Banerjee P., Becker K.G., Freed W.J., and Kanthasamy A.G. Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem. Int. 50 (2007) 834-847
2. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., Bogousslavsky J., and Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9 (2003) 1180-1186
3. Brecht S., Kirchhof R., and Chromik A. Specific pathophysiological functions of JNK isoforms in the brain. Eur. J. Neurosci. 21 (2005) 363-377
4. Brint E.K., Fitzgerald K.A., Smith P., Coyle A.J., Gutierrez-Ramos J.C., Fallon P.G., and O'Neill L.A. Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction. J. Biol. Chem. 277 (2002) 49205-49211
5. Centeno C., Repici M., and Chatton J.Y. Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons. Cell. Death. Differ. 14 (2007) 240-253
6. Clinton S.M., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am. J. Psychiatry 160 (2003) 1100-1109
7. Gareskog M., and Wentzel P. N-Acetylcysteine and alpha-cyano-4-hydroxycinnamic acid alter protein kinase C (PKC)-delta and PKC-zeta and diminish dysmorphogenesis in rat embryos cultured with high glucose in vitro. J. Endocrinol. 192 (2007) 207-214
8. Giustizieri M., Cucchiaroni M.L., Guatteo E., Bernardi G., Mercuri N.B., and Berretta N. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta. J. Pharmacol. Exp. Ther. 322 (2007) 721-729
9. Gundersen H.J., Jensen E.B., Kieu K., and Nielsen J. The efficiency of systematic sampling in stereology-reconsidered. J. Microsc. 193 (1999) 199-211
10. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., and Davis R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15 (1996) 2760-2770
11. Hara M.R., Thomas B., Cascio M.B., Bae B.I., Hester L.D., Dawson V.L., Dawson T.M., Sawa A., and Snyder S.H. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3887-3889
12. Hayley S., Crocker S.J., Smith P.D., Shree T., Jackson-Lewis V., Przedborski S., Mount M., Slack R., Anisman H., and Park D.S. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 24 (2004) 2045-2053
13. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., and Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 665-670
14. Irving E.A., and Bamford M. Role of mitogen- and stress-activated kinases in ischemic injury. J. Cerebr. Blood Flow Metab. 22 (2002) 631-647
15. Jha N., Kumar M.J., Boonplueang R., and Andersen J.K. Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease?. J. Neurochem. 80 (2002) 555-561
16. Kamath R., Jiang Z., Sun G., Yalowich J.C., and Baskaran R. c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase. Mol. Pharmacol. 71 (2007) 61-72
17. Kawahara Y., Kawahara H., and Westerink B.H. Hypotension-induced dopamine release in prefrontal cortex is mediated by local glutamatergic projections at the level of nerve terminals. J. Neurochem. 81 (2002) 285-291
18. Kooncumchoo P., Sharma S., Porter J., Govitrapong P., and Ebadi M. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J. Mol. Neurosci. 28 (2006) 125-141
19. Kress G.J., and Reynolds I.J. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol. Dis. 20 (2005) 639-645
20. Kuan C.Y., Whitmarsh A.J., and Yang D.D. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15184-15189
21. Li X., Yang D., Li L., Peng C., Chen S., and Le W. Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem. Int. 50 (2007) 959-965
22. Mulle C., Sailer A., Pérez-Otaño I., Dickinson-Anson H., Castillo P.E., Bureau I., Maron C., Gage F.H., Mann J.R., Bettler B., and Heinemann S.F. Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice. Nature 392 (1998) 601-605
23. Namgung U., and Xia Z. Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase. J. Neurosci. 20 (2000) 6442-6451
24. Pan J., Zhang Q.G., and Zhang G.Y. The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region. Neuroscience 31 (2005) 147-159
25. Pan J., Zhao Y.X., Wang Z.Q., Jin L., Sun Z.K., and Chen S.D. Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Neurosci. Lett. 428 (2007) 82-87
26. Pan J., Wang G., Yang H.Q., Hong Z., Xiao Q., Ren R.J., Zhou H.Y., Bai L., and Chen S.D. K252a prevents nigral dopaminergic cell death induced by 6-OHDA through inhibition of both MLK3/JNK3 and ASK1/JNK3 signaling pathways. Mol. Pharmacol. 72 (2007) 1607-1618
27. Pei D.S., Wang X.T., Liu Y., Sun Y.F., Guan Q.H., Wang W., Yan J.Z., Zong Y.Y., Xu T.L., and Zhang G.Y. Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence. Brain 129 (2006) 465-479
28. Qanungo S., Starke D.W., Pai H.V., Mieyal J.J., and Nieminen A.L. Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NF{kappa}B. J. Biol. Chem. 282 (2007) 18427-18436
29. Rameau G.A., Tukey D.S., Garcin-Hosfield E.D., Titcombe R.F., Misra C., Khatri L., Getzoff E.D., and Ziff E.B. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J. Neurosci. 27 (2007) 3445-3455
30. Repici M., and Borsello T. JNK pathway as therapeutic target to prevent degeneration in the central nervous system. Adv. Exp. Med. Bill. 588 (2006) 145-155
31. Ries V., Silva R.M., Oo T.F., Cheng H.C., Rzhetskaya M., Kholodilov N., Flavell R.A., Kuan C.Y., Rakic P., and Burke R.E. JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J. Neurochem. 107 (2008) 1578-1588
32. Schwarzschild M.A., Cole R.L., and Hyman S.E. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons. J. Neurosci. 17 (1997) 3455-3466
33. Setsuie R., and Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int. 51 (2007) 105-111
34. Tuneva E.O., Bychkova O.N., and Boldyrev A.A. Effect of NMDA on production of reactive oxygen species by human lymphocytes. Bull. Exp. Biol. Med. 136 (2003) 159-161
35. Waetzig V., and Herdegen T. The concerted signaling of ERK1/2 and JNKs is essential for PC12 cell neuritogenesis and converges at the level of target proteins. Mol. Cell. Neurosci. 24 (2003) 238-249
36. West B.D., Shughrue P.J., Vanko A.E., Ransom R.W., and Kinney G.G. Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment. Pharmacol. Biochem. Behav. 84 (2006) 158-161
37. Wu S.S., and Frucht S.J. Treatment of Parkinson's disease: what's on the horizon?. CNS Drugs 19 (2005) 723-743
38. Yang D.D., Kuan C.Y., Whitmarsh A.J., Rinconm M., Zheng T.S., Davis R.J., Rakic P., and Flavell R.A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389 (1997) 865-870
39. Yoshizumi M., Kogame T., Suzaki Y., Fujita Y., Kyaw M., Kirima K., Ishizawa K., Tsuchiya K., Kagami S., and Tamaki T. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br. J. Pharmacol. 136 (2002) 1023-1032
40. Zhu Y., Hoell P., Ahlemeyer B., Sure U., Bertalanffy H., and Krieglstein J. Implication of PTEN in production of reactive oxygen species and neuronal death in vitro models of stroke and Parkinson's disease. Neurochem. Int. 50 (2007) 507-516